CANCER

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

Next Investors Archived Oct 24, 2019

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

City of Hope receives US DoD grant with upside for Imugene

Finfeed Archived Oct 23, 2019

A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.

Ten ‘TechKnows’ to test drive

Finfeed Archived Oct 23, 2019

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Next Investors Archived Oct 02, 2019

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

Genetic Technologies surges 40% on back of agreement

Finfeed Archived Sep 23, 2019

Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

A healthy six pack in a hot sector: Part 1

Finfeed Archived Sep 10, 2019

Finfeed has come up with six stocks in the healthcare and bioscience sectors that appear to have plenty going for them in fiscal 2020.

Imagion shares up 12% on the back of today's Magsense news

Finfeed Archived Sep 09, 2019

Imagion’s shares received a boost with strong trading throughout the morning resulting in an increase from the previous day’s close of 4.1 cents to 4.5 cents just before midday.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Podcast: How Imagion is bringing cancer diagnostics into the 21st century

Finfeed Archived Aug 28, 2019

Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

Next Investors Archived Aug 14, 2019

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

Rhythm Biosciences making progress in 1000 patient trial

Finfeed Archived Aug 07, 2019

Rhythm Biosciences Ltd (ASX:RHY) is continuing to develop its global, low-cost, lifesaving blood test for the detection of colorectal cancer, ColoSTAT®.

ONJ, medical cannabis and a nod to Australian cannabis stocks

Finfeed Archived Aug 05, 2019

Today, as a man who writes a lot about medical cannabis and related listed companies, my interest is always piqued by medical cannabis based human interest stories.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Next Investors Archived Jul 25, 2019

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Invion: Making a dynamic play in cancer treatment

Finfeed Archived May 23, 2019

Drug delivery company Invion Limited (ASX:IVX) is leading the way in developing PhotosoftTM technology for the treatment of a range of cancers.

GTG Validates Cancer Tests As it Looks to Global Expansion

Next Investors Archived May 14, 2019

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).